HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.

HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Abstract Text:

Rameshwer Shukla,Thommey P Thomas,Jennifer L Peters,Ankur M Desai,Jolanta Kukowska-Latallo,Anil K Patri,Alina Kotlyar,James R Baker,

In the present study, we report the synthesis and human growth factor receptor-2 (HER2) specific tumor targeting properties of a dendrimer conjugated to anti-HER2 mAb (monoclonal antibody) conjugate. The polyamidoamine (PAMAM) dendrimer generation five (G5) was labeled with alexaFluor 488 and conjugated to anti-HER2 mAb. The binding and internalization of the antibody-conjugated dendrimer to HER2-expressing cells was evaluated by flow cytometry and confocal microscopy. Uniquely, the conjugate demonstrated cellular uptake and internalization in HER2-expressing cells as compared to free antibody. The time course of internalization and blocking experiments with free antibody suggest that the rapid and efficient cellular internalization of the dendrimer-antibody conjugate was achieved without alterations in specificity of targeting. Animal studies demonstrated that the conjugate targets HER2-expressing tumors.

HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Publishing Authors By Initials

R Shukla,TP Thomas,JL Peters,AM Desai,J Kukowska-Latallo,AK Patri,A Kotlyar,JR Baker,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Bioconjugate chemistry

VOLUME: 17

Page Numbers: 1109-15

Journal Abbreviation:

ISSN: 1043-1802

DAY: 3

MONTH: 12

YEAR: 2007

HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9010319

HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.

AFFILIATION: Michigan Nanotechnology Institute for Medicine and Biological Sciences, Department of Internal Medicine, Division of Allergy, University of Michigan, 9220 MSRB III, Box 0648, Ann Arbor, 48109, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Bioconjug Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb Related Publications

• A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.
• A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
• AUTO3DEM--an automated and high throughput program for image reconstruction of icosahedral particles.
• Ab initio random model method facilitates 3D reconstruction of icosahedral particles.
• An accelerated state of myosin-based actin motility.
• Analyses of RAS Regulation of Eye Development in Drosophila melanogaster.
• Assessing tobacco dependence: a guide to measure evaluation and selection.
• Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care.
• Dendrimer-based targeted delivery of an apoptotic sensor in cancer cells.
• Deubiquitinating activity of the SARS-CoV papain-like protease.
• Effect of opening midlevel neonatal intensive care units on the location of low birth weight births in California.
• Enhancement of natural and experimental respiratory mycoplasmosis in rats by hexamethylphosphoramide.
• Evaluation of public health response to hurricanes finds North Carolina better prepared for public health emergencies.
• HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.
• HPLC analysis of functionalized poly(amidoamine) dendrimers and the interaction between a folate-dendrimer conjugate and folate binding protein.
• HPLC separation of different generations of poly(amidoamine) dendrimers modified with various terminal groups.
• Health literacy and health risk behaviors among older adults.
• Hyperoxic and hyperbaric-induced cardioprotection: role of nitric oxide synthase 3.
• Hypoxia-inducible factor 1 in lower limb ischemia.
• Inmate-made weapons in prison facilities: assessing the injury risk.
• Iopamidol-induced meningoencephalopathy in an HIV-seropositive patient.
• Modulation of the antioxidant defence as a factor in apoptosis.
• Ovarian response, ova recovery and fertility in merino ewes superovulated either during the luteal phase of their oestrous cycle or after intravaginal progestagen treatment.
• Phosphodiesterase-5 inhibitors and omental and placental small artery function in normal pregnancy and pre-eclampsia.
• Protein polymorphism and the rate of loss of duplicate gene expression.
• Resurfacing flaps in reconstructive rhinoplasty.
• Superovulation in the prepuberal calf.
• T cell receptor binding transition states and recognition of peptide/MHC.
• T cell receptor recognition via cooperative conformational plasticity.
• Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies.